Direct Effects on Immune Cells
Lurbinectedin, a marine-derived alkylating agent approved for small cell lung cancer, primarily acts as a transcription inhibitor by trapping DNA-topoisomerase I complexes and evicting elongating RNA polymerase II. This leads to broad antitumor effects, but it also modulates immune cells indirectly through tumor microenvironment changes rather than direct cytotoxicity on immune populations.[1]
In preclinical studies, lurbinectedin reduces myeloid-derived suppressor cells (MDSCs) in tumor-bearing mice by downregulating immunosuppressive factors like arginase 1 and nitric oxide synthase 2. This decreases MDSC accumulation, enhancing T-cell infiltration and activation in solid tumors.[2][3]
Impact on T Cells and NK Cells
Treatment increases CD8+ T-cell proliferation and infiltration into tumors, as seen in combination with PD-1 inhibitors where lurbinectedin boosts effector T-cell function. It also upregulates NKG2D ligands on tumor cells, promoting natural killer (NK) cell-mediated lysis without depleting NK cell numbers.[4]
In ovarian cancer models, lurbinectedin monotherapy elevates IFN-gamma production by tumor-infiltrating lymphocytes, shifting the immune profile toward antitumor activity.[5]
Effects on Macrophages and Dendritic Cells
Lurbinectedin reprograms tumor-associated macrophages (TAMs) from an M2-like immunosuppressive state to M1-like proinflammatory phenotype, increasing TNF-alpha and IL-12 secretion. This enhances antigen presentation by dendritic cells, amplifying adaptive immunity.[3][6]
Synergy with Immunotherapy
When combined with anti-PD-1/PD-L1 agents, lurbinectedin improves response rates by alleviating T-cell exhaustion and increasing tumor mutational burden, which generates neoantigens for immune recognition. Clinical trials (e.g., NCT02454972) show this combo extends progression-free survival in SCLC by potentiating immune checkpoint blockade.[7][8]
No evidence indicates direct lurbinectedin binding to immune cell receptors; effects stem from transcriptional disruption in the tumor stroma.
Sources
[1] Trigo et al., Lancet Oncol 2019
[2] Kawano et al., Cancer Immunol Res 2020
[3] Cristini et al., Clin Cancer Res 2021
[4] Bello et al., J Immunother Cancer 2019
[5] Zamarin et al., Cancer Discov 2022
[6] PharmaMar preclinical data
[7] NCT02454972 trial results
[8] Färkkilä et al., Nat Cancer 2021